Coherus Biosciences Company Profile (NASDAQ:CHRS)

About Coherus Biosciences (NASDAQ:CHRS)

Coherus Biosciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CHRS
  • CUSIP: N/A
  • Web: www.coherus.com
Capitalization:
  • Market Cap: $1.04 billion
  • Outstanding Shares: 51,288,000
Average Prices:
  • 50 Day Moving Avg: $20.32
  • 200 Day Moving Avg: $24.28
  • 52 Week Range: $14.00 - $31.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.06
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $177.91 million
  • Price / Sales: 5.82
  • Book Value: $1.52 per share
  • Price / Book: 13.29
Profitability:
  • EBIDTA: ($120,850,000.00)
  • Net Margins: -52.04%
  • Return on Assets: -47.08%
Debt:
  • Debt-to-Equity Ratio: 3.15%
  • Current Ratio: 3.04%
  • Quick Ratio: 3.04%
Misc:
  • Average Volume: 564,245 shs.
  • Beta: 4.82
  • Short Ratio: 7.63
 

Frequently Asked Questions for Coherus Biosciences (NASDAQ:CHRS)

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) announced its quarterly earnings results on Monday, May, 8th. The company reported ($1.54) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.54). The firm earned $0.16 million during the quarter. View Coherus Biosciences' Earnings History.

Where is Coherus Biosciences' stock going? Where will Coherus Biosciences' stock price be in 2017?

7 brokers have issued 12-month target prices for Coherus Biosciences' stock. Their predictions range from $38.00 to $54.00. On average, they anticipate Coherus Biosciences' stock price to reach $42.71 in the next year. View Analyst Ratings for Coherus Biosciences.

What are analysts saying about Coherus Biosciences stock?

Here are some recent quotes from research analysts about Coherus Biosciences stock:

  • 1. Maxim Group analysts commented, "Amgen (as expected) filed suit against Coherus claiming violations of the Neulasta Patent ‘707 (purification process)." (5/15/2017)
  • 2. Credit Suisse Group AG analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities. Positives from the 4Q16 release that support our thesis: 1) In November of ’16, ACRS reported that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions. In February 2017, ACRS submitted a New Drug Application NDA for A-101 40% Topical Solution for the treatment of SK to the FDA. 2) During ’16 ACRS also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts. 3) ACRS recently completed a Phase 1 clinical trial of ATI-50001, its investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis. And, 4) ACRS had cash and cash equivalents of $174.1MM as of 12/31/16." (3/16/2017)
  • 3. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (2/16/2017)

Who are some of Coherus Biosciences' key competitors?

Who owns Coherus Biosciences stock?

Coherus Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (4.32%), Wellington Management Group LLP (2.48%), State Street Corp (2.18%), UBS Asset Management Americas Inc. (1.76%) and JHL Capital Group LLC (1.36%). Company insiders that own Coherus Biosciences stock include Alan C Herman, August J Troendle, Christos Richards, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus Biosciences.

Who sold Coherus Biosciences stock? Who is selling Coherus Biosciences stock?

Coherus Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, VHCP Management II LLC, Chicago Equity Partners LLC, Cornerstone Capital Management Holdings LLC., Russell Investments Group Ltd., SG Americas Securities LLC, Alliancebernstein L.P. and TD Asset Management Inc.. Company insiders that have sold Coherus Biosciences stock in the last year include Alan C Herman, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Insider Buying and Selling for Coherus Biosciences.

Who bought Coherus Biosciences stock? Who is buying Coherus Biosciences stock?

Coherus Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., JHL Capital Group LLC, UBS Asset Management Americas Inc., TIAA CREF Investment Management LLC, State Street Corp, Principal Financial Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Coherus Biosciences.

How do I buy Coherus Biosciences stock?

Shares of Coherus Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Coherus Biosciences stock cost?

One share of Coherus Biosciences stock can currently be purchased for approximately $20.20.

Analyst Ratings

Consensus Ratings for Coherus Biosciences (NASDAQ:CHRS) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $42.71 (111.46% upside)

Analysts' Ratings History for Coherus Biosciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/21/2017Barclays PLCReiterated RatingOverweight$46.00HighView Rating Details
5/17/2017Citigroup IncSet Price TargetBuy$38.00HighView Rating Details
5/15/2017BMO Capital MarketsReiterated RatingOutperform$54.00N/AView Rating Details
5/15/2017Maxim GroupSet Price TargetBuy$43.00MediumView Rating Details
4/21/2017Credit Suisse Group AGReiterated RatingBuy$38.00HighView Rating Details
2/1/2017Robert W. BairdReiterated RatingOutperform$40.00N/AView Rating Details
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00N/AView Rating Details
3/1/2016JPMorgan Chase & Co.Lower Price TargetOverweight$37.00 -> $35.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Coherus Biosciences (NASDAQ:CHRS)
Earnings by Quarter for Coherus Biosciences (NASDAQ:CHRS)
Earnings History by Quarter for Coherus Biosciences (NASDAQ:CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($1.54)($1.54)$0.16 millionViewListenView Earnings Details
3/13/2017Q4 2016($1.11)($1.71)$10.00 million$0.84 millionViewListenView Earnings Details
11/9/2016Q3 2016($1.56)$1.67$7.20 million$162.80 millionViewListenView Earnings Details
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)$12.36 millionViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)$8.63 million$10.20 millionViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 million$6.87 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 million$5.81 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus Biosciences (NASDAQ:CHRS)
Current Year EPS Consensus Estimate: $-5.13 EPS
Next Year EPS Consensus Estimate: $-2.23 EPS

Dividends

Dividend History for Coherus Biosciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Coherus Biosciences (NASDAQ:CHRS)
Insider Ownership Percentage: 32.88%
Institutional Ownership Percentage: 64.52%
Insider Trades by Quarter for Coherus Biosciences (NASDAQ:CHRS)
Institutional Ownership by Quarter for Coherus Biosciences (NASDAQ:CHRS)
Insider Trades by Quarter for Coherus Biosciences (NASDAQ:CHRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Alan C HermanInsiderSell11,333$20.73$234,933.09View SEC Filing  
1/25/2017Jean-Frederic ViretCFOSell3,900$27.00$105,300.00View SEC Filing  
12/16/2016Jean-Frederic ViretCFOSell3,900$28.30$110,370.00View SEC Filing  
12/8/2016Mats WahlstromDirectorSell53,583$27.52$1,474,604.16View SEC Filing  
12/1/2016Alan C HermanInsiderSell11,333$27.40$310,524.20View SEC Filing  
10/21/2016Jean-Frederic ViretCFOSell3,900$30.62$119,418.00View SEC Filing  
10/3/2016Alan C HermanInsiderSell11,333$25.69$291,144.77View SEC Filing  
9/26/2016Jean-Frederic ViretCFOSell3,900$29.88$116,532.00View SEC Filing  
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.00View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.00View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Coherus Biosciences (NASDAQ:CHRS)
Latest Headlines for Coherus Biosciences (NASDAQ:CHRS)
Source:
DateHeadline
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Stock Rating Reaffirmed by Barclays PLC
www.americanbankingnews.com - May 21 at 9:28 AM
rttnews.com logoCoherus BioSciences Inc. (CHRS) Leaped After Patent Victory
www.rttnews.com - May 18 at 11:13 AM
finance.yahoo.com logoAbbVie Down on Humira Patent Loss: Is More Damage in Store?
finance.yahoo.com - May 18 at 11:13 AM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Given a $38.00 Price Target at Citigroup Inc
www.americanbankingnews.com - May 17 at 8:32 PM
nasdaq.com logoCoherus BioSciences Prevails in '135 IPR Decision - NASDAQ.com - Nasdaq
www.nasdaq.com - May 17 at 4:23 PM
finance.yahoo.com logoAbbVie Stock Lower on Humira Patent Ruling
finance.yahoo.com - May 17 at 11:38 AM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 1:08 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 15 at 10:14 AM
nasdaq.com logoAre Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock? - Nasdaq
www.nasdaq.com - May 12 at 10:04 PM
finance.yahoo.com logoCoherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : May 12, 2017
finance.yahoo.com - May 12 at 10:04 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock?
finance.yahoo.com - May 12 at 4:51 PM
finance.yahoo.com logoCoherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : May 11, 2017
finance.yahoo.com - May 11 at 4:56 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Expected to Post Earnings of -$1.40 Per Share
www.americanbankingnews.com - May 11 at 4:23 PM
americanbankingnews.com logoMaxim Group Analysts Give Coherus Biosciences Inc (CHRS) a $43.00 Price Target
www.americanbankingnews.com - May 10 at 12:16 AM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Issues Earnings Results, Hits Expectations
www.americanbankingnews.com - May 9 at 1:38 PM
finance.yahoo.com logoEdited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 8:19 AM
finance.yahoo.com logoCoherus BioSciences reports 1Q loss
finance.yahoo.com - May 8 at 9:11 PM
finance.yahoo.com logoInvestor Network: Coherus BioSciences, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 4:10 PM
finance.yahoo.com logoCoherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results
finance.yahoo.com - May 8 at 4:10 PM
finance.yahoo.com logoThe Prospects For CHS-3351, Coherus' Most Underappreciated Asset
finance.yahoo.com - May 5 at 4:30 PM
americanbankingnews.com logoBMO Capital Markets Initiates Coverage on Coherus Biosciences Inc (CHRS)
www.americanbankingnews.com - May 5 at 11:16 AM
finance.yahoo.com logoCoherus BioSciences Management to Present at Two Investor ... - Yahoo Finance
finance.yahoo.com - May 3 at 8:26 AM
americanbankingnews.com logoCoherus Biosciences (CHRS) Earns Daily Media Sentiment Rating of 0.07
www.americanbankingnews.com - May 2 at 12:52 PM
finance.yahoo.com logoCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in May
finance.yahoo.com - May 1 at 4:16 PM
americanbankingnews.com logoCoherus Biosciences (CHRS) Earning Somewhat Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 27 at 7:24 PM
americanbankingnews.com logoCoherus Biosciences' (CHRS) "Buy" Rating Reaffirmed at Credit Suisse Group AG
www.americanbankingnews.com - April 27 at 7:20 AM
streetinsider.com logoCoherus BioSciences (CHRS) Announces Patent Dance Exchange with Amgen (AMGN) for Neulasta Biosimilar
www.streetinsider.com - April 25 at 4:08 PM
finance.yahoo.com logoETFs with exposure to Coherus BioSciences, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 4:08 PM
finance.yahoo.com logoCoherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
finance.yahoo.com - April 25 at 12:14 PM
americanbankingnews.com logoCoherus Biosciences (CHRS) Receives News Sentiment Rating of -0.11
www.americanbankingnews.com - April 24 at 2:36 PM
finance.yahoo.com logoCoherus BioSciences to Report First Quarter 2017 Financial Results on May 8th
finance.yahoo.com - April 24 at 9:35 AM
americanbankingnews.com logoCoherus Biosciences (CHRS) Getting Somewhat Positive News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 2:13 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Expected to Post Earnings of -$1.54 Per Share
www.americanbankingnews.com - April 20 at 8:27 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 18 at 2:08 PM
americanbankingnews.com logoCoherus Biosciences (CHRS) Getting Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 17 at 2:54 PM
americanbankingnews.com logoCoherus Biosciences (CHRS) Given Media Sentiment Rating of 0.31
www.americanbankingnews.com - April 14 at 9:21 AM
finance.yahoo.com logoETFs with exposure to Coherus BioSciences, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:59 AM
finance.yahoo.com logoETFs with exposure to Coherus BioSciences, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:59 AM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Insider Sells $234,933.09 in Stock
www.americanbankingnews.com - April 5 at 8:31 PM
finance.yahoo.com logoCoherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development
finance.yahoo.com - March 27 at 4:14 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 24 at 2:23 PM
finance.yahoo.com logoCOHERUS BIOSCIENCES, INC. Financials
finance.yahoo.com - March 17 at 3:45 PM
finance.yahoo.com logoEdited Transcript of CHRS earnings conference call or presentation 13-Mar-17 8:30pm GMT
finance.yahoo.com - March 14 at 12:06 PM
biz.yahoo.com logoCOHERUS BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 14 at 12:06 PM
rttnews.com logoEARNINGS SUMMARY: Details of Coherus Biosciences, Inc. Q4 Earnings Report
www.rttnews.com - March 13 at 4:24 PM
us.rd.yahoo.com logoCoherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results
us.rd.yahoo.com - March 13 at 4:24 PM
biz.yahoo.com logoCOHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - March 13 at 4:24 PM
biz.yahoo.com logoCoherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 13 at 4:24 PM
biz.yahoo.com logoQ4 2016 Coherus BioSciences Inc Earnings Release - After Market Close
biz.yahoo.com - March 13 at 12:41 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) to Release Earnings on Monday
www.americanbankingnews.com - March 10 at 9:36 PM

Social

Chart

Coherus Biosciences (CHRS) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff